Product Introduction: DAPAKING -GM2 FORTE XR

DAPAKING -GM2 FORTE XR is an advanced triple-combination antidiabetic medication manufactured by Alkem. Composed of 10mg of Dapagliflozin (an SGLT2 inhibitor), 2mg of Glimepiride (a sulfonylurea), and 1000mg of Metformin Hydrochloride Extended-Release (XR), it is indicated for glycemic control in adult patients diagnosed with Type 2 Diabetes Mellitus when dual combination therapy is insufficient.

Primary Indications

• Management of Type 2 Diabetes Mellitus in adults for optimal glycemic control.
• Improving insulin secretion, reducing insulin resistance, and restricting glucose reabsorption.
• Reducing the long-term risk of diabetic microvascular and macrovascular complications.

Clinical Benefits

• Triple Pathway Control: Glimepiride stimulates insulin release, Metformin reduces hepatic glucose, and Dapagliflozin promotes glucose excretion in urine.
• Weight & BP Reductions: Dapagliflozin aids in moderate calorie loss and blood pressure reduction through glucosuria.
• Extended-Release Metformin: Smooth, gradual drug release minimizes gastrointestinal side effects.

Possible Side Effects

Common side effects may include:

• Gastrointestinal issues (nausea, metallic taste, abdominal bloating, transient diarrhea).
• Genitourinary tract infections (such as vulvovaginal candidiasis or urinary tract infections) due to glucose in urine.
• Hypoglycemia (low blood sugar), especially when co-administered with sulfonylureas or insulin.

How to Take DAPAKING -GM2 FORTE XR

• Take the tablet daily, with or immediately after your morning meal to minimize stomach upset and prevent hypoglycemia.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split.
• Maintain adequate hydration to prevent dehydration and urinary tract infections.

Mechanism of Action

DAPAKING -GM2 FORTE XR works through three distinct mechanisms:

• Dapagliflozin: Inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion.
• Glimepiride: Binds to ATP-sensitive potassium channels on pancreatic beta-cells, causing depolarization and opening of calcium channels, triggering the release of insulin.
• Metformin: Decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.

Safety Warnings

• Lactic Acidosis: Metformin carries a rare but serious risk of lactic acidosis. Avoid in severe renal impairment.
• Renal Function: Dapagliflozin efficacy is dependent on kidney function. Avoid in severe renal impairment.
• Pregnancy & Nursing: Strictly contraindicated. Avoid use.

Patient Advice

• Always carry a rapid-acting source of sugar (like glucose powder or fruit juice) in case of hypoglycemia.
• Maintain high standards of personal hygiene to prevent genital fungal infections.
• Drink plenty of water (8-10 glasses) daily to stay well-hydrated.

Fact Box

Drug Interactions

• Insulin & Sulfonylureas: Concomitant use increases the risk of hypoglycemia; lower doses may be required.
• Diuretics (Loop): May increase the risk of dehydration and hypotension.
• Iodinated Contrast Media: Increased risk of lactic acidosis; hold Metformin temporarily.

User Feedback

• Patients report excellent control of blood glucose levels, with many noting beneficial weight loss and cardiovascular stability.
• Initial stomach bloating is common but typically fades away after 7 to 10 days of consistent use.